Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · August 15, 2023

Effect of SGLT2 Inhibitor Use on Amputation Risk Across Categories of Baseline Cardiovascular Disease and Diuretics Use in Patients With Type 2 Diabetes

Diabetes, Obesity & Metabolism


Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes, Obesity & Metabolism
Safety of sodium-glucose co-transporter-2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes
Diabetes Obes Metab 2023 Jul 28;[EPub Ahead of Print], S Park, HE Jeong, S Bea, OHY Yu, YM Cho, SC You, KKC Man, JY Shin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading